Interim report
Page 1
October 3 0 , 2026 To, Listing Operation Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001 (Scrip Code: 544644) To, Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, C - 1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400051 ( SYMBOL : CORONA) Dear Sir / Ma dam, Sub.: Outcome of the Board Meeting Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the S ecurities and E xchange B oard of I ndia (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), w e would like to inform that based on the recommendation of the Audit Committee , the Board at its meeting held today has, inter alia, approved the u naudited standalone and consolidated f inancial r esults along with limited review report s of the Company for the second quarter and half year end ed on September 3 0 , 202 6 . The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an advertisement for u naudited s tandalone and consolidated f inancial r esults for the second quarter and half year end ed on September 3 0 , 202 6 . The above r esults along with limited review report s are also being made available on the website of the Company at www.coronaremedies.com A Press Release on financial results which is being submitted to the media, is also enclosed herewith. The Board meeting commenced at 0 3 : 3 0 p.m. and concluded at 0 4 : 4 0 p.m. You are requested to take note of the above. Thanking you . Yours f aithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl .: A/a
Page 2
Walker Chandiok &Co LLP Walker Chandiok & Co LLP Block No. DASth Floor, Cabin No. A8 to A0 “West Gate” Near YMCA Club, S.G Highway, Sarkhej Road, Ahmedabad-380015 Gujarat, India Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obiigations and Disciosure Requirements) Reguiations, 2015 (as amended) To the Board of Directors of CORONA Remedies Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement’) of CORONA Remedies Limited (Formerly known as CORONA Remedies Private Limited) (‘the Company’) for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations’). 2. The Statement, which is the responsibility of the Company’s management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that right be identified in an audit. Accordingly, we do not express an audit opinion. ZERep Recy ‘Chafered Accountants Walker Chandiok & Co LLP s registered with limited liability with identification Offes In Abmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennal, Debradun, Goa, Gurugram, Guaahat, Hyderabad, Indore, number AAC-2085 and has its registered Kochi, Kokata, Mumbal, New Delhi, Noida and Pune. office at L41, Connaught Circus, Outer Circle, New Delri, 110001, India
Page 3
Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)(cont’d) 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 30 September 2025 and audit of standalone financial results for the year ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who has expressed unmodified conclusion vide their review report dated 02 January 2026 and unmodified opinion vide their audit report dated 11 May 2026, respectively, whose reporis have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 ’ > AL Mehufkumar Sharadkumar Janani Partner Membership No. 118617 UDIN : 26118617HEJLGT5745 Place : Ahmedabad Date : 30 October 2026 Charered Accountants Walker Chandiok & Co LLP is registered vith limited liability with identification Offces in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Defradun, Goa, Gurugram, Guwahat, Hyderebad, Indore, number AAC-2085 and has its registered Koehi, Kokt Mumbai, New Del, Noida and Pune office at L41, Connaught Circus, Outer Circle, New Delhi, 110001, India
Page 4
CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) Regd. Office: CORONA House, C - Mondeal Business Park, Near Gurudwara, $.G. Highway, Thaltej. Ahmedabad-380059, Gujarat, India - Tele.: +079-40233000 | Website : www.coronaremedics.com CIN : 124231G12004PLCO44656. Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30 September 2026 (Amount Rs. in Crores except pet share data) | For Quarter Ended For Half Year Ended___|For Year Ended| . Par 30 September [ 1 T30 September | 30 September [ 30 September [ 466 No. 2026 Trasiicl) 2025 2026 2025 ) (Unaudited) (Unaudited) | (Unaudited) | (Unaudited) - T |Income: Revenue from operations 44117 42243 36113 863.60 707.67 1,403.18 Other income 248 315 227 5.63 429 1065 Total income 443.65 42558 363.40 869.23 711.96 1,413.83 2 |Expenses : Cost of materials consumed 3501 32.65 25.90 67.66 50.97 10351 Purchases of Stock-in-trade 6824 5720 211 125.44 6288 150,38 |Changes in inventorics of finished goods, stock-in-trade and 270 233 . P 2058 705 work-in-progress Employee benefits expense 12424 122.09 103.00 246.33 20044 403.02 Finance costs 275 2.69 193 544 3.9 697 Depreciation and amortization expenses 15.06 1324 920 28.30 18.12 37.87 Other expenses 14047 129.69 11101 27016 224.55 445.78 ‘Total expenses 363.03 34523 293.79 | _ 581.46 115458 3 |Profit before exceptional item and tax (1-2) 80.62 80.35 69.61 16097 130.50 259.25 4 |Exceptional item : Statutory impact of new Labour Codes (Refer note 4) - - - - - (19.10) 5 [Profit before tax (3+4) 80.62 8035 69.61 16097 13050 240.15 6 |Tax expense: Current tax 18.43 1838 1585 3681 30.15 5148 Deferred tax 201 187 161 3.88 180 380 Total Tax expense 20.44 20.25 17.46 40.69 31.95 55.30 7 |Net Profit after tax for the period / year (5-6) 60.18 60.10 5215 12028 98.55 184.85 3 |Other comprehensive income / (loss) for the period/year lItems that will not be reclassified to profit or loss Remeasurement of net defined benefit plans 0.96) (0.40) 041 (1.36) (0.67) 015 Income tax effect on above 024 0.10 (©.10) 034 017 (0.04) ;l"t;ml other comprehensive income / (loss) for the period/year, net of 0 030 031 0 050 o1 9 [Total comprehensive income for the period/year (7+8) 59.46 59.80 5245 11926 98.05 184.96 10 |Paid-up equity share capital (face value Rs.10/-) 6116 61.16 61.16 6116 61.16 6116 11 |Other Equity 68481 12 [Earnings per share (not annualised for the quarter and half year) Basic (Rs.) 984 983 8.53 19.67 1611 3022 Diluted (Rs.) 9.84 9.83 8.53 19.67 16.11 3022 LA N (S \e) © (AHmEDABAD) E} oo\/é/;) *
Page 5
Unaudited Statement of Standalone Assets and Liabilitics as at 30 Scptember 2026 Amount Rs. in Crores) As at As at Particulars 30 September 2026 31 March 2026 (Unaudited) (Audited) A. ASSETS: 1. Non-current assets a. Property, plant and equipment 42523 291,14 b. Capital work-in-progress 21.83 143.12 c. Other intangible assets 246.94 262.83 d. Financial assets i. Investments 2539 2540 ii. Loans - 0.01 iii. Other financial assets 50.86 129.87 . Other non-current assets 177 3.57 Total non-current assets 772.02 855.94 2. Current assets a. Inventories 170.69 125.00 b. Financial assets Trade receivables 170.61 145.55 Cash and cash equivalents 1.58 1.83 iii. Bank balances other than cash and cash equivalents 97.21 42.29 iv. Loans 0.11 0.26 v. Other financial assets 0.12 0.30 . Other current assets 33.36 33.08 ‘Total current assets 473.68 348.31 ' TOTAL ASSETS 1,245.70 1,204.25 B. Ef BILITIES: 1. Equity a. Equity share capital 61.16 61.16 b. Other equity 742.91 684.81 Total equity 804.07 74597 Liabilities 2. Non-current liabilities a. Financial liabilities i. Borrowings 025 - ii. Lease liabilities 17.29 18.88 b. Provisions 75.40 66.07 c. Deferred tax liabilities (net) 15.69 12.16 'Total non-current liabilities 108.63 97.11 3. Current liabilities a. Financial liabilities i. Borrowings 94.28 142.86 ii. Lease liabilities 3.34 311 iii. Trade payables total outstanding dues of micro enterprises and small enterprises 8.16 9.85 total outstanding dues of creditors other than micro enterprise and small enterprise 107.50 80.48 iv. Other financial liabilities 63.99 76.46 b. Other current liabilities 8.38 6.99 c. Provisions. 35.69 33.04 d. Current tax liabilities (net) 1166 8.38 Total current liabilities 333.00 361.17 Total liabilities 441.63 458.28 1,245.70 1,204.25 [ TOTAL EQUITY AND LIABILITIES
Page 6
‘Unaudited Statement of Standalone Cash Flows for the Half Year ended 30 September 2026 (Amount Rs. in Crores) For Half Year ended | For Half Year ended Particulars September 2026 September 2025 (Unaudited) (Unaudited) Cash flow from operating act Profit before tax 160.97 130.50 Adiustments fo Depreciation and amortization expenses 28.30 18.12 Finance costs 544 3.92 Interest income “.719) (2.76) Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL) 0.01 (0.04) (Gain) / loss on sale/disposal of fixed assets 011) 043 Provision for expected credit loss 0.05 0.05 Provision for inventory obsolescence written back (0.96) (1.03) Bad debts written off 0.01 0.05 Liabilities written back - (0.06) 615 483 Provision for expiry and breakage sales return Net Unrealized exchange Gain (0.25)] (0.24; Operating profit before working capital changes 194.82 153.77 Changes in working capital Decrease/ (Increase) in inventories (44.73)) 2322 Decrease/ (Increase) in trade receivables (24.79)) (41.66)| Decrease / (Increase) in other current assets (0.28) 558 Decrease / (Increase) in other financial assets 0.17 (8.51); Decrease / (Increase) in non-current assets (0.02); 0.04 Decrease in loans. 0.16 021 (Decrease) / Increase in other financial liabilities (10.17) 1.48 Increase in provisions 447 2.86 (Decrease) / Increase in trade payables 25.24 (3.24) Increase in other current liabilities 1.39 229 Cash generated from operations 146.26 136.04 Income taxes paid (Net) (33.53) (22.60) Net cash generated from operating activities (A) 112.73 11344 Cash flow from Investing activities Payment for property, plant and equipment and intangible assets including capital work-in-progress, ! - ! (26.33) (32.51) capital advance and creditors for capital goods Proceeds from sale/ disposal of fixed assets 0.74 047 Fixed deposits placed / (matured) 24.10 (12.04) Interest received 479 2.76 Net cash generated from / (used in) investing acti 3.30 (41.32) Cash flow from Financing activi Payment of dividend (61.16) (44.71) Proceeds from long-term borrowings 0.25 - Repayment of long-term borrowings (16.00) (18.00) Repayment of short-term borrowings (32.58) .11 Interest paid (4.25) 3.27) Payment towards lease liability (excluding interest) (1.52) 1.37) Interest on lease liability (1.02) (1.09) Net cash (used in) financing activities (C) (116.28) (73.55) Net (decrease) in cash and cash equivalents (A+B+C) (0.25), (1.43) Effect of exchange differences on restatement of foreign currency Cash and cash equivalents* 0.00 0.01 Cash and cash equivalents at the beginning of the period 1.83 3.22 Cash and cash equivalents at the end of the period 1.58 1.80 | *Effect of exchange differences on restatement of forcign currency Cash and cash equivalents for the half year ended 30 Scptember 2026 represents amounting Rs.29,696/- For Half Year ended | For Half Year ended Particulars Scptember 2026 | September 2025 (Unaundited) (Unaudited) Cash and cash equivalents comprise Balances with banks: In current accounts. 0.09 0.30 Fixed deposits with maturity of less than 3 months 0.01 - Cheques on hand 141 145 Cash on hand 0.07 0.05 | Total cash and bank balances at end of the period 1.58
Page 7
Notes to Standalone Financial Results for the Quarter and Half Year ended 30 September 2026 : 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an ssue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per cquity share (other than employees) by selling sharcholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling sharcholders. The above standalone unaudited financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 30 October 2026. These standalone financial resuls have been prepared in accordance with the recognition and measurement principles laid down.in the Indian Accounting Standard 34 [*Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted.in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended. On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the ycar ended 31 March 2026. The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as nceded. The Company has only one reportable business segment namely - ‘Pharmaceuticals’ as determined by the Chief Operating Decision Maker in accordance with the Ind AS 108-"Operating Segment". The figures for the corresponding previous periods have becn regrouped/reclassified wherever necessary, to make them comparable. As at 30 September 2026, the Company held fixed deposits aggregating to Rs. 146.82 Crores (comprising Rs. 49.68 Crores under other non-current financial assets, Rs. 0.01 Crores under cash and cash equivalents and Rs. 97.13 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 94.28 Crores were availed and disclosed under short-term borrowings. For {ORONA Remedies Limited, Niray K. Mehta e Managing Director & CEQ VA m N DIN : 01644041 ) <\ (S (pvimeDazAD) 3 ) Place: Ahmedabad Date : 30 October 2026 >/ O, 3/ A
Page 8
Walker Chandiok &Co LLP Walker Chandiok & Co LLP Block No. D/15th ~ Floor, Cabin No. A8 to A10 “West Gate” Near YMCA Club, S.G Highway, Sarkhej Road, Ahmedabad-380015 Guijarat, India Independent Auditor’s Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Resuits of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of CORONA Remedies Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results (‘the Statement’) of CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) (‘the Holding Company’) and its associate (refer Annexure 1 for the list of associate included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations’). 2. This Statement, which is the responsibility of the Holding Company’s management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. AR =g Walker Chandiok & Co LLP is registered with limited lizbiity with identification Ofices in Ahmedabad, Bengalury, Bhubanestwar, Chandigarh, Chennal, Dehvadun, Goa, Gurugra, Guwaha Hyderabad,Indore, number AAC-2085 and has ts registered Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune. office at L-41, Connaugnt Circus, Outer Circle, New Delni, 110001, India Chatiored Accoutants
Page 9
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd) 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditor referred to in paragraph 5, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The Statement also includes the Holding Company’s share of net profit after tax of Z 0.13 crores and % 0.14 crores and total comprehensive income of ¥ 0.01 crores and Z 0.01 crores, for the quarter and year-to-date period ended on 30 September 2026, respectively, as considered in the Statement, in respect of one (1) associate, whose financial results have not been reviewed by us. This financial results have been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor. 6. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 30 September 2025 and audit of consolidated financial results for the year ended 31 March 2026 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified conclusion vide their review report dated 02 January 2026 and unmodified opinion vide their audit report dated 11 May 2026, respectively, whose report has been furnished to us by the management, and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration Noy: 001076N/N500013 M Gevnnd Mehulkumar Sharadkumar Janani Partner Membership No. 118617 UDIN : 26118617UFJSEJ7230 Place : Ahmedabad Date : 30 October 2026 Chartered Accourtans. ‘Walker Chandiok & Co LLP is registered with limited liability with identlication Offces in Anmedabad, Bengalury, Bhubaneswar, Chandigarh, Chennai Dehradun, Goa, Gurugram, Guwaha, Hyderabad, Indore, number AAC-2085 and has its registered Kochi, Kolkata, Mumb, New Del, Noida and Pure. office at L-41, Connaught Circus, Outer Circle. New Dekhi, 110001, India
Page 10
Independent Auditor’s Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI Listing Obligations and Disclosure Re: R i d Annexure 1 List of the entities included in Statement Sr.No | Entity Name Relationship 1. CORONA Remedies Limited Holding Company 2. La Chandra Pharma Lab Private Limited Associate e 5 2 i f . T Sy Chartered Accountants ‘Walker Chandiok & Co LLP is registered with limited fability wilh identfication Offces in Ahmegabad, Bengalury, Bhubaneswar, Chandigarh, Chennai, Dehvadun, Goa, Gurugram, Gunwahat, Hyderabad, Indore, number AAC-2085 and has Its registered Koch, Kolkata, Mumoa, New Deli, Noida and Pune: office at L41, Connaught Circus, Outer Circle, New Delhi, 110001, Incia
Page 11
‘CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) Regd. Office: CORONA House, C - Mondeal Business Park, Near Gurudwara, S.G Highway, Thaltej, Ahmedabad-380059, Gujarat, India Tele.: +079-40233000 | Website : www.coronaremedies.com CIN :124231GJ2004PLC044656 Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30 September 2026 (Amount Rs. in Crores except per share data) For Quarter Ended For Half Year Ended___|For Year Ended| sr. — 30 September | 1o [ 30 September [ 30 September [ 30 September [\ No. 2026 e 2025 2026 2025 i (Unaudited) (Unaudited) | (Unaudited) | (Unaudited) o T | Income : Revenue from operations 44117 42243 361.13 863.60 707.67 1,403.18 Other income 248 305 227 563 429 10.65 Total income 443.65 42558 363.40 869.23 71196 1,413.83 2 |Expenses : Cost of materials consumed 3501 32.65 25.90 67.66 50.97 103.51 Purchases of Stock-in-trade 68.24 5720 28.11 125.44 62.88 150.38 Changes in inventories of finished goods, stock-in-trade and. (@274 (12.33)] 14.64 (35.07) 20.58 705 work-in-progress [Employee benefits expense 124.24 122.09 103.00 24633 200.44 403.02 Finance costs 275 2.69 193 5.44 392 6.97 Depreciation and amortization expenses 15.06 1324 9.20 28.30 18.12 37.87 Other expenses 140.47 129.69 111.01 270.16 22455 445.78 Total expenses 363.03 345.23 293.79 708.26 581.46 1,154.58 3 zrxfl:ill ;):lore Share of profit/(loss) of associate, exceptional item and 80.62 80.35 69.61 160.97 130.50 259.25 4 |Exceptional item : Statutory impact of new Labour Codes (Refer note 4) - - - - - (19.10)) 5 |Share of profit/(loss) of associate (net of tax) 0.13 0.01 017 0.14 (0.03)) 027 6 |Profit before tax (3+4+5) 80.75 8036 69.78 16111 13047 240.42 7 nse s Current tax 1843 18.38 15.85 3681 3015 5148 Deferred tax 2.01 1.87 161 3.88 1.80 3.82 Total Tax expense 2044 20.25 17.46 40.69 31.95 55.30 8 |Net Profit after tax for the period / year (6-7) 60.31 60.11 52.32 120.42 98.52 185.12 9 |Other comprehensive income / (loss) for the period/year ltems that will not be reclassified to profit o loss Remeasurement of net defined benefit plans (0.96) (0.40), 0.41 (1.36)] (0.67)] 0.15 Income tax cffect on above 024 0.10 ©.10) 034 017 ©.04) Share of other comprehensive income / (loss) of associate (net of )| 001 0.00 (0.00) 001 - 0.00 'll;ox(l] other comprehensive income / (loss) for the period/year, net of ©.71) (0.30) 031 .o (0.50) 011 10 |Total comprehensive income for the period/year (8+9) 59.60 59.81 52.63 119.41 98.02 185.23 11 |Profit for the year/period attributable to: (Owners of the Company 60.31 60.11 52.32 120.42 98.52 185.12 6031 60.11 5232 12042 98.52 185.12 12 |Other comprehensive income / (loss) for the period/year attributable to: (Owners of the Company (0.71) (0.30); 0.31 (101} (0.50)] 0.11 (0.71), (0.30)] 0.31 (1.01) (0.50)] 0.11 13 |Total comprehensive income for the period/year attributable to: |Owners of the Company 59.60 59.81 52.63 119.41 98.02 185.23 59.60 59.81 52.63 119.41 98.02 185.23 14 |Paid-up equity share capital (face value Rs.10/-) 61.16 61.16 61.16 61.16 61.16 61.16 15 |Other Equity 685.70 16 |Earnings per share (not annualised for the quarter and half year) Basic (Rs.) 986 983 855 19.69 16.11 3027 Diluted (Rs.) 986 983 855 19.69 1611 3027 \o. (2 (anmeDABAD
Page 12
Unaudited Statcment of Consolidated Assets and Liabilities as at 30 September 2026 ‘Amount Rs. in Crores) Asat Asat Particulars 30 September 2026 31 March 2026 (Unaudited) (Audited) A. ASSET: 1. Non-current assets . Property, plant and equipment 42523 29114 b. Capital work-in-progress 21.83 143.12 c. Other intangible assets 246.94 262.83 d. Investments accounted using equity method 26.27 26.12 c. Financial assets i. Investments 0.16 0.17 ii. Loans - 0.01 iii. Other financial assets 50.86 129.87 f. Other non-current assets 1.77 3.57 Total non-current assets. 773.06 856.83 2. Current assets a. Inventories 170.69 125.00 b. Financial assets . Trade receivables 170.61 145.55 ii. Cash and cash equivalents 1.58 1.83 iii. Bank balances other than cash and cash equivalents 97.21 42.29 iv. Loans 0.11 0.26 v. Other financial assets 0.12 0.30 c. Other current assets 33.36 33.08 Total current assets 473.68 34831 TOTAL ASSETS 1,246.74 1,205.14 B. EQUITY AND LIABILITIES: 1. Equity 2. Equity share capital 61.16 61.16 b. Other equity 743.95 685.70 Total equity 805.11 746.86 Liabilities 2. Non-current liabilities a. Financial liabilities i. Borrowings 0.25 - ii. Lease liabilities 17.29 18.88 b. Provisions 75.40 66.07 c. Deferred tax liabilities (net) 15.69 12.16 Total non-current lial 108.63 97.11 3. Current liabilities a. Financial liabilities i. Borrowings 94.28 142.86 ii. Lease liabilities 334 311 iii. Trade payables - total outstanding dues of micro enterprises and small enterprises 8.16 9.85 - total outstanding dues of creditors other than micro enterprise and small enterprise 107.50 80.48 iv. Other financial liabilities 63.99 76.46 b. Other current liabilities 8.38 6.99 c. Provisions 35.69 33.04 d. Current tax liabilities (net) 11.66 838 Total current liabilities 333.00 361.17 Total liabilities 441,63 458.28 TOTAL EQUITY AND LIABILITIES 1,246.74 1,205.14
Page 13
Unaudited Statement of Cons idated Cash Flows for the Half Year ended 30 September 2026 (Amount Rs. in Crores For Half Year ended | For Half Year ended Particulars September 2026 September 2025 (Unaudited) (Unaudited) Cash flow from operating acti Profit before tax 16111 13047 Adjustments fo Share of loss / (profit) from Associate (0.14) 0.03 Depreciation and amortization expenses 2830 18.12 Finance costs 544 392 Interest income (.79 (2.76) Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL) 0.01 (0.04) (Gain) / loss on sale/disposal of fixed assets (©.11) 043 Provision for expected credit loss 005 005 Provision for inventory obsolescence written back (0.96) (1.03) Bad debts written off 0.01 0.05 Liabilities written back - (0.06) Provision for expiry and breakage sales retum 6.15 483 Net Unrealized exchange Gain 0.25) (024) Operating profit before working capital changes 194.82 153.77 Changes in working capital Decrease (Increase) in inventories (44.73) 2322 Decrease! (Increase) in trade receivables (24.79) (41.66) Decrease / (Increase) in other current assets (0.28) 5.58 Decrease / (Inerease) in other financial assets 017 (8.51) Decrease / (Increase) in non-current assets (0.02) 0.04 Decrease in loans 0.16 021 (Decrease) / Increase in other financial liabilities (10.17) 148 Increase in provisions 447 286 (Decrease) / Increase in trade payables 2524 (3.24) Increase in other current liabilities 139 229 Cash generated from operations 146.26 136.04 Income taxes paid (Net) (33.53) (22.60) Net cash generated from operating activities () 112.73 113.44 Cash flow from Investing activities Payment for property, plant and equipment and intangible assets including capital work-in- . . N (26.33) (32.51)) progress, capital advance and creditors for capital goods Procceds from sale/ disposal of fixed assets 0.74 047 Fixed deposits placed / (matured) 24.10 (12.04) Interest received 4.79 2.76 Net cash generated from / (used in) investing activities (B) 330 (@132 Cash flow from Financing activities Payment of dividend (61.16) (44.71) Proceeds from long-term borrowings 025 - Repayment of long-term borrowings (16.00) (18.00) Repayment of short-term borrowings (32.58) (5.11) Interest paid (4.25) (3.27) Payment towards lease liability (excluding interest) (1.52) (1.37) Interest on lease liability (1.02) (1.09) Net cash (used in) financing activities (C) (116.28) (7355 Net (decrease) in cash and cash equivalents (A+B+C) (0.25) (1.43) Effect of exchange differences on restatement of foreign currency Cash and cash equivalents® 0.00 0.01 Cash and cash equivalents at the beginning of the period 183 322 Cash and cash cquivalents at the end of the period 1.58 1.80 *Effect of exchange differences on restatement of forcign currency Cash and cash equivalents for the half year ended 30 September 2026 represents amounting Rs.29,696/- For Half Year ended | For Half Year ended Particulars September 2026 September 2025 (Unaudited) (Unaudited) Cash and cash cquivalents comprise Balances with banks: In current accounts 0.09 030 Fixed deposits with maturity of less than 3 months 0.01 - Cheques on hand 141 145 Cash on hand 007 0.05 Total cash and bank balances at end of the period 158 1.80
Page 14
Notes to Consolidated Financial Results for the Quarter and Half Year ended 30 September 2026 : 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Tnitial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling sharcholders. The total initial public offer expenses (except lsting fees) are entirely allocated to the selling shareholders. 2 The above consolidated unaudited financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 30 October 2026. 3 These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended. 4 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes” under “Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026. The incremental impact consisting of grafuity of Rs.13.60 crores and long:-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects. of the Labour Code and would provide appropriate accounting cffect on the basis of such developments as needed. S The Company has only one reportable business segment namely - ‘Pharmaceuticals’ as determined by the Chief Operating Decision Maker in accordance with the Ind AS 108-"Operating Segment”. 6 The figures for the corresponding previous periods have been regrouped/reclassified wherever necessary, to make them comparable. 7 As at 30 September 2026, the Company held fixed deposits aggregating to Rs. 146.82 Crores (comprising Rs. 49.68 Crores under other non-current financial assets, Rs. 0.01 Crores under cash and cash equivalents and Rs. 97.13 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 94.28 Crores were availed and disclosed under short-term borrowings. For {ORONA Remedies Limited, \ v Nirav K. Mehta Managing Dircctor & CEO DIN : 01644041 Place: Ahmedabad Date : 30 October 2026
Page 15
PRESS RELEASE CORONA Remedies delivers highest ever Revenue with growth of 22% for Q2FY27 on Y-o-Y basis, 1.9x the IPM growth Ahmedabad, October 30, 2026: CORONA Remedies Limited, one of the fastest growing companies amongst Top 30 Indian pharmaceutical companies, has announced its unaudited financial result for quarter & half year ended September 30, 2026. Financial Performance Snapshot: Particulars (₹ in Cr) Q2FY27 Q2FY26 Y-o-Y (%) H1FY27 H1FY26 Y-o-Y (%) Revenue from Operations 441.2 361.1 22.2% 863.6 707.7 22.0% EBITDA 96.0 78.5 22.3% 189.1 148.2 27.5% EBITDA Margin (%) 21.7% 21.7% - 21.9% 20.9% - Profit After Tax* 60.3 52.3 15.3% 120.4 98.5 22.2% PAT Margin* (%) 13.7% 14.5% - 13.9% 13.9% - *PAT & PAT Margins were lower on account of higher depreciation & amortization charge for our newly commissioned facilities & acquisition of brands, from which revenue contribution are expected to build up over the coming quarters. Key Business Highlights: Outpacing IPM Growth1: CORONA continues to be one of the fastest growing companies among T op 30 companies of IPM as per MAT Sep’26 1. CORONA has outperformed market by 1.9 times for MAT Sep’261. CORONA is at 14th rank in its Covered Market and at 26th rank in overall IPM. Focus on brand building: CORONA now has 4 brands exceeding ₹ 100 crores in annual sales, including 1 brand crossing ₹ 200 crores as per MAT Sep’26 1. Operational excellence and disciplined execution: Leveraging all growth drivers to outperform IPM. Volume growth 2x higher than IPM, Pricing 1.5x higher, and New Introductions 2.4x higher than IPM for MAT Sep’26 1. Outperforming Chronic Business: Chronic + Semi Chronic contribution stands at 71.2% for Q2 FY27 against 67.7% in Q2 FY26, as per MAT Sep’261. Growth of Chronic + Semi Chronic is ~350 bps higher than company growth. ANVISA GMP Certification: Company has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad, covering both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing excellence towards its philosophy of ‘ONE WORLD ONE QUALITY’ 1: Pharmatrac MAT Sep’26
Page 16
Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. Revenue grew 22.2% year-on-year in Q2FY27 and 22% in H1FY27, ahead of our stated guidance. Our domestic business grew at 22.9%, well ahead of the Indian Pharmaceutical Market (IPM) growth of 12%, and our chronic portfolio grew at nearly twice the rate of its market segment. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence and investing in capabilities that will support our future growth. The Indian pharmaceutical industry is underpinned by strong structural demand drivers. Backed by our diversified portfolio, established brands, expanding market reach and experienced leadership team, we are well positioned to capitalise on these opportunities and sustain our growth momentum. ”
Page 17
About CORONA Remedies Limited Founded in 2004, CORONA Remedies Limited is an India-focused pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas, including Women’s Healthcare, Cardio-Diabetes, Pain Management, and Urology. The company has established a strong presence in the Indian pharmaceutical market through its focus on scientific expertise, brand building, manufacturing excellence, and quality-driven operations. Its manufacturing facilities and research capabilities support its commitment to delivering high-quality healthcare solutions. Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management ‘s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to diƯer materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its aƯiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an oƯer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. For further information please contact Company Investor Relations Advisors CORONA Remedies Limited CIN No: L24231GJ2004PLC044656 Chetna Dharajiya – Company Secretary & Compliance OƯicer Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Sagar ShroƯ / Tanay Shah Email id: sagar.shroƯ@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899